San Diego-based Pathway Genomics is the latest lab to participate in creating a registry of cancer patients who have undergone complex genetic testing. The agreement between Pathway and the Prospective Registry of Multiplex Testing, or PROMPT, was announced late last month. PROMPT is being managed by physicians and scientists from the University of Pennsylvania, the Dana Farber Cancer Institute, the Mayo Clinic, and Memorial Sloan-Kettering Cancer Center. It collects data from patients who have undergone multigene panels—including those who have been determined to have an elevated risk for cancer—and uses it to determine what the risks and outcomes are for patients based on how they test for cancer-related genes. The data may be identified or deidentified at the discretion of each patient and their family. The initial undertaking of the PROMPT initiative is to create a cohort of individuals and families who have consented to participate in studies examining cancer-causing genetic mutations. It launched its patient portal in July and began collecting patient data in late summer. “We are honored to collaborate with the country’s leading cancer experts to help advance the understanding of cancer risk, the genes associated with it, and take steps to end preventable hereditary cancers,” said […]
San Diego-based Pathway Genomics is the latest lab to participate in creating a registry of cancer patients who have undergone complex genetic testing.
The agreement between Pathway and the Prospective Registry of Multiplex Testing, or PROMPT, was announced late last month. PROMPT is being managed by physicians and scientists from the University of Pennsylvania, the Dana Farber Cancer Institute, the Mayo Clinic, and Memorial Sloan-Kettering Cancer Center. It collects data from patients who have undergone multigene panels—including those who have been determined to have an elevated risk for cancer—and uses it to determine what the risks and outcomes are for patients based on how they test for cancer-related genes. The data may be identified or deidentified at the discretion of each patient and their family.
The initial undertaking of the PROMPT initiative is to create a cohort of individuals and families who have consented to participate in studies examining cancer-causing genetic mutations. It launched its patient portal in July and began collecting patient data in late summer.
“We are honored to collaborate with the country’s leading cancer experts to help advance the understanding of cancer risk, the genes associated with it, and take steps to end preventable hereditary cancers,” said David Becker, Pathway Genomics’ chief scientific officer.
Pathway provides testing for breast cancer mutations beyond BRCA (which is excluded from the PROMPT agreement) and also conducts analyses of genetic changes and variants among family members to determine if there is a specific link between them and medical conditions.
Pathway Genomics is among several laboratories in the United States that is participating in the PROMPT registry. Ambry Genetics and Myriad Genetics are among the other participants. They joined PROMPT last June.
Takeaway: A patient registry of those who have undergone multigene panel testing is beginning to pick up momentum by obtaining participation from the larger laboratories.
